Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

    Summary
    EudraCT number
    2020-000077-25
    Trial protocol
    PL   NL   CZ  
    Global end of trial date

    Results information
    Results version number
    v1(current)
    This version publication date
    27 Apr 2024
    First version publication date
    27 Apr 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    I5T-MC-AACI
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04437511
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    Trial Number: 17737
    Sponsors
    Sponsor organisation name
    Eli Lilly and Company
    Sponsor organisation address
    Lilly Corporate Center, Indianapolis, IN, United States, 46285
    Public contact
    Available Mon ‐ Fri 9 AM ‐ 5 PM EST, Eli Lilly and Company, 1 877‐CTLilly,
    Scientific contact
    Available Mon ‐ Fri 9 AM ‐ 5 PM EST, Eli Lilly and Company, 1 877‐285‐4559,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    14 Apr 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    14 Apr 2023
    Global end of trial reached?
    No
    General information about the trial
    Main objective of the trial
    The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.
    Protection of trial subjects
    This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    19 Jun 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 17
    Country: Number of subjects enrolled
    Canada: 137
    Country: Number of subjects enrolled
    Czechia: 22
    Country: Number of subjects enrolled
    Japan: 88
    Country: Number of subjects enrolled
    Netherlands: 22
    Country: Number of subjects enrolled
    Poland: 159
    Country: Number of subjects enrolled
    United Kingdom: 39
    Country: Number of subjects enrolled
    United States: 1252
    Worldwide total number of subjects
    1736
    EEA total number of subjects
    203
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    176
    From 65 to 84 years
    1531
    85 years and over
    29

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Not Applicable

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Subject

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Donanemab
    Arm description
    Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks
    Arm type
    Experimental

    Investigational medicinal product name
    Donanemab
    Investigational medicinal product code
    Other name
    LY3002813
    Pharmaceutical forms
    Injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    Participants received 700 mg Donanemab Q4W x 3 doses, then 1400 mg Q4W given IV for up to 72 weeks.

    Arm title
    Placebo
    Arm description
    Participants received placebo given IV.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    Participants received placebo given IV.

    Number of subjects in period 1
    Donanemab Placebo
    Started
    860
    876
    Received at Least One Dose of Drug
    853
    874
    Completed
    622
    698
    Not completed
    238
    178
         Adverse event, serious fatal
    15
    10
         Consent withdrawn by subject
    111
    94
         Physician decision
    19
    10
         Adverse event, non-fatal
    50
    21
         Progressive Disease
    4
    7
         Withdrawal due to Caregiver Circumstances
    21
    20
         Lost to follow-up
    11
    11
         Continuing Study
    7
    5

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Donanemab
    Reporting group description
    Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks

    Reporting group title
    Placebo
    Reporting group description
    Participants received placebo given IV.

    Reporting group values
    Donanemab Placebo Total
    Number of subjects
    860 876 1736
    Age categorical
    Units: Subjects
    Age continuous
    All randomized participants.
    Units: years
        arithmetic mean (standard deviation)
    72.98 ( 6.16 ) 73.04 ( 6.20 ) -
    Gender categorical
    All randomized participants.
    Units: Subjects
        Female
    493 503 996
        Male
    367 373 740
    Ethnicity (NIH/OMB)
    All randomized participants.
    Units: Subjects
        Hispanic or Latino
    35 36 71
        Not Hispanic or Latino
    583 594 1177
        Unknown or Not Reported
    242 246 488
    Race (NIH/OMB)
    All randomized participants.
    Units: Subjects
        American Indian or Alaska Native
    2 0 2
        Asian
    57 47 104
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    19 21 40
        White
    781 807 1588
        More than one race
    0 1 1
        Unknown or Not Reported
    1 0 1
    Region of Enrollment
    All randomized participants.
    Units: Subjects
        Australia
    13 4 17
        Canada
    64 73 137
        Czechia
    12 10 22
        Japan
    45 43 88
        Netherlands
    13 9 22
        Poland
    77 82 159
        United Kingdom
    16 23 39
        United States
    620 632 1252
    Screening Tau Category
    All randomized participants who have only evaluable Screening Tau category data. Intermediate tau (Low-medium): All participants with baseline composite tau PET standardized uptake value ratio (SUVr) <= 1.46 and a topographic deposition pattern consistent with advanced AD (AD++) or 1.10 <= SUVr <= 1.46 and a topographic deposition pattern consistent with moderate AD (AD+). High tau: All participants with SUVr >1.46 and a topographic deposition pattern consistent with either moderate (AD+) or advanced AD (AD++).
    Units: Subjects
        Intermediate (Low-medium)
    588 594 1182
        High
    271 281 552
        Missing
    1 1 2
    Integrated Alzheimer's Disease Rating Scale (iADRS)
    Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance.
    Units: Score on a scale
        arithmetic mean (standard deviation)
    104.10 ( 14.30 ) 103.60 ( 14.02 ) -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Donanemab
    Reporting group description
    Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks

    Reporting group title
    Placebo
    Reporting group description
    Participants received placebo given IV.

    Primary: Change from Baseline on the integrated Alzheimer’s Disease Rating Scale (iADRS) (Overall population)

    Close Top of page
    End point title
    Change from Baseline on the integrated Alzheimer’s Disease Rating Scale (iADRS) (Overall population)
    End point description
    Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. Least Squares (LS) Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline acetylcholinesterase inhibitor (AchI)/Memantine use. Analysis population description (APD) included all randomized participants with a baseline and at least one postbaseline iADRS data point.
    End point type
    Primary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    775
    824
    Units: score on a scale
        least squares mean (standard error)
    -10.19 ( 0.53 )
    -13.11 ( 0.50 )
    Statistical analysis title
    Change from Baseline on iADRS
    Statistical analysis description
    Overall population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1599
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    2.92
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.508
         upper limit
    4.331
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.72

    Primary: Change from Baseline on the integrated Alzheimer’s Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)

    Close Top of page
    End point title
    Change from Baseline on the integrated Alzheimer’s Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)
    End point description
    Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use. APD included all randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline iADRS data point.
    End point type
    Primary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    533
    560
    Units: score on a scale
        least squares mean (standard error)
    -6.02 ( 0.50 )
    -9.27 ( 0.49 )
    Statistical analysis title
    Change from Baseline on iADRS
    Statistical analysis description
    Intermediate (Low-medium) Tau Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1093
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    3.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.883
         upper limit
    4.618
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.7

    Secondary: Change from Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population)

    Close Top of page
    End point title
    Change from Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population)
    End point description
    MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use. APD included all randomized participants with a baseline and at least one postbaseline MMSE data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    796
    841
    Units: score on a scale
        least squares mean (standard error)
    -2.47 ( 0.14 )
    -2.94 ( 0.13 )
    Statistical analysis title
    Change from Baseline on MMSE Score
    Statistical analysis description
    Overall Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1637
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.012
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    0.47
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.104
         upper limit
    0.841
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.19

    Secondary: Change from Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population)

    Close Top of page
    End point title
    Change from Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population)
    End point description
    MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use. APD included all randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline MMSE data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    549
    573
    Units: score on a scale
        least squares mean (standard error)
    -1.61 ( 0.14 )
    -2.09 ( 0.14 )
    Statistical analysis title
    Change from Baseline on MMSE Score
    Statistical analysis description
    Intermediate (Low-medium) Tau Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1122
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.016
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    0.48
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.089
         upper limit
    0.868
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.2

    Secondary: Change from Baseline on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13) (Overall Population)

    Close Top of page
    End point title
    Change from Baseline on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13) (Overall Population)
    End point description
    The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-cog consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use. APD included all randomized participants with a baseline and at least one postbaseline ADAS-Cog13 data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    797
    841
    Units: score on a scale
        least squares mean (standard error)
    5.46 ( 0.28 )
    6.79 ( 0.27 )
    Statistical analysis title
    Change from Baseline on ADAS-Cog13
    Statistical analysis description
    Overall Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1638
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0006
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -1.33
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.086
         upper limit
    -0.565
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.39

    Secondary: Change from Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population)

    Close Top of page
    End point title
    Change from Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population)
    End point description
    CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, baseline tau category, pooled investigator, and baseline AchI/Memantine use. APD included all randomized participants with a baseline and at least one postbaseline CDR-SB data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    794
    838
    Units: score on a scale
        least squares mean (standard error)
    1.72 ( 0.096 )
    2.42 ( 0.092 )
    Statistical analysis title
    Change from Baseline on CDR-SB
    Statistical analysis description
    Overall Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1632
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -0.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.95
         upper limit
    -0.45
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.127

    Secondary: Change from Baseline on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population)

    Close Top of page
    End point title
    Change from Baseline on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population)
    End point description
    The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use. APD included all randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline ADAS-Cog13 data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    550
    570
    Units: score on a scale
        least squares mean (standard error)
    3.17 ( 0.27 )
    4.69 ( 0.26 )
    Statistical analysis title
    Change from Baseline on ADAS-Cog13
    Statistical analysis description
    Intermediate (Low-medium) Tau Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1120
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -1.52
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.25
         upper limit
    -0.794
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.37

    Secondary: Change from Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population)

    Close Top of page
    End point title
    Change from Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population)
    End point description
    CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, pooled investigator, and baseline AchI/Memantine use. APD included all randomized participants with baseline Intermediate Tau level and with baseline and at least one postbaseline CDR-SB data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    546
    569
    Units: score on a scale
        least squares mean (standard error)
    1.20 ( 0.105 )
    1.88 ( 0.102 )
    Statistical analysis title
    Change from Baseline on CDR-SB
    Statistical analysis description
    Intermediate (Low-medium) Tau Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1115
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -0.67
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.95
         upper limit
    -0.4
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.141

    Secondary: Change from Baseline on the Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population)

    Close Top of page
    End point title
    Change from Baseline on the Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population)
    End point description
    The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use. APD included all randomized participants with a baseline and at least one postbaseline ADCS-iADL data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    780
    826
    Units: score on a scale
        least squares mean (standard error)
    -4.42 ( 0.32 )
    -6.13 ( 0.30 )
    Statistical analysis title
    Change from Baseline on ADCS-iADL Score
    Statistical analysis description
    Overall Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1606
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    1.7
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.84
         upper limit
    2.566
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.44

    Secondary: Change from Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan

    Close Top of page
    End point title
    Change from Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan
    End point description
    Florbetapir or florbetaben PET imaging was used as a quantitative amyloid biomarker. Amyloid PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical brain regions relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, baseline tau category, and age at baseline.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76 APD included all randomized participants with a baseline and at least one postbaseline amyloid PET scan data point.
    End point values
    Donanemab Placebo
    Number of subjects analysed
    765
    812
    Units: centiloids
        least squares mean (standard error)
    -87.03 ( 0.950 )
    -0.67 ( 0.909 )
    Statistical analysis title
    Change from Baseline in Brain Amyloid Plaque
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1577
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -86.37
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -88.87
         upper limit
    -83.87
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.275

    Secondary: Change from Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan

    Close Top of page
    End point title
    Change from Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan
    End point description
    Flortaucipir PET imaging was used as a quantitative tau biomarker. Tau PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in aggregated tau neurofibrillary tangles (NFTs). Quantitative tau burden was formalized using Standardized Uptake Value Ratio (SUVR) in frontal lobe relative to the cerebellum gray as a reference region. Larger SUVR reflects larger tau burden in the frontal lobe relative to cerebellum gray. LS Mean value was adjusted for baseline score, screening tau category, age and treatment (Type III sum of squares). APD included all randomized participants with a baseline and post-baseline tau PET scan.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    578
    654
    Units: standardized uptake value ratio (SUVR)
        least squares mean (standard error)
    0.0401 ( 0.00398 )
    0.0442 ( 0.00374 )
    Statistical analysis title
    Change from Baseline in Brain Tau Deposition
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.4522
    Method
    ANCOVA
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -0.0041
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -0.0148
         upper limit
    0.0066

    Secondary: Change from Baseline in Brain Volume as Measured by volumetric Magnetic Resonance Imaging (vMRI)

    Close Top of page
    End point title
    Change from Baseline in Brain Volume as Measured by volumetric Magnetic Resonance Imaging (vMRI)
    End point description
    MRI scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in brain volume. Volumetric MRI parameters were measured in bilateral hippocampus, bilateral whole brain, and bilateral ventricles. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline tau category, and age at baseline. APD included all randomized participants with a baseline and at least one postbaseline vMRI data point
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    786
    831
    Units: cubic centimeter (cm^3)
    least squares mean (standard error)
        Bilateral Hippocampus
    -0.20 ( 0.005 )
    -0.22 ( 0.005 )
        Bilateral Whole Brain
    -27.46 ( 0.409 )
    -20.79 ( 0.392 )
        Bilateral Ventricles
    10.07 ( 0.185 )
    7.05 ( 0.178 )
    Statistical analysis title
    Change from Baseline in Brain Volume by vMRI
    Statistical analysis description
    Bilateral Hippocampus
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1617
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.002
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    0.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.01
         upper limit
    0.04
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.007
    Statistical analysis title
    Change from Baseline in Brain Volume by vMRI
    Statistical analysis description
    Bilateral Whole Brain
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1617
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    -6.66
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -7.76
         upper limit
    -5.56
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.561
    Statistical analysis title
    Change from Baseline in Brain Volume by vMRI
    Statistical analysis description
    Bilateral Ventricles
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1617
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    3.02
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    2.52
         upper limit
    3.52
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.256

    Secondary: Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab

    Close Top of page
    End point title
    Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab [1]
    End point description
    The average serum concentration at steady state, calculated as Cav = AUCtau/tau, where tau is the dosing interval (4 weeks). APD included all randomized participants who received at least one dose of study drug and had evaluable PK data.
    End point type
    Secondary
    End point timeframe
    Predose: Week 4, 8, 12, 16, 24, 36, 52, 64; Postdose: Week 0, 12, 24, 52 and random at week 76
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: PK endpoint is evaluated only for Donanemab.
    End point values
    Donanemab
    Number of subjects analysed
    853
    Units: micrograms per milliliter (μg/mL)
        geometric mean (geometric coefficient of variation)
    63 ( 32 )
    No statistical analyses for this end point

    Secondary: Number or Participants with Anti-Donanemab Antibodies

    Close Top of page
    End point title
    Number or Participants with Anti-Donanemab Antibodies
    End point description
    Number of participants with treatment-emergent positive Anti-Donanemab antibodies was summarized by treatment group. APD included all randomized participants who received at least one dose of study drug and had evaluable anti-drug antibody measurement.
    End point type
    Secondary
    End point timeframe
    Baseline through Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    793
    821
    Units: participants
    693
    48
    No statistical analyses for this end point

    Secondary: Change From Baseline on the Alzheimer’s Disease Cooperative Study – Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population)

    Close Top of page
    End point title
    Change From Baseline on the Alzheimer’s Disease Cooperative Study – Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population)
    End point description
    The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use. APD included all randomized participants with a baseline Intermediate Tau level and with baseline and at least one postbaseline ADCS-iADL data point.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 76
    End point values
    Donanemab Placebo
    Number of subjects analysed
    535
    562
    Units: score on a scale
        least squares mean (standard error)
    -2.76 ( 0.34 )
    -4.59 ( 0.32 )
    Statistical analysis title
    Change from Baseline on ADAS-iADL Score
    Statistical analysis description
    Intermediate (Low-medium) Tau Population
    Comparison groups
    Donanemab v Placebo
    Number of subjects included in analysis
    1097
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.001
    Method
    Mixed models analysis
    Parameter type
    LS Mean change difference (Final Values)
    Point estimate
    1.83
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.913
         upper limit
    2.748
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.47

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Baseline Up To 76 Weeks plus 57 Days (Follow-up period) Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    Adverse event reporting additional description
    Safety population included all randomized participants who received at least one dose of study drug. There were 25 deaths reported in subject disposition and 26 deaths in All-cause mortality, because 1 participant death occurred in the plus 57-day follow-up period was considered as completer in the study disposition period.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.1
    Reporting groups
    Reporting group title
    Donanemab
    Reporting group description
    Participants received 700 mg Donanemab Q4W x 3 doses, then 1400 mg Q4W given IV for up to 72 weeks.

    Reporting group title
    Placebo
    Reporting group description
    Participants received placebo given IV.

    Serious adverse events
    Donanemab Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    148 / 853 (17.35%)
    138 / 874 (15.79%)
         number of deaths (all causes)
    16
    10
         number of deaths resulting from adverse events
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    adenocarcinoma pancreas
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    bladder cancer
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    bladder papilloma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    breast cancer stage i
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cervix carcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed [1]
    0 / 488 (0.00%)
    1 / 501 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    choroid melanoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    diffuse large b-cell lymphoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    endometrial adenocarcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed [2]
    1 / 488 (0.20%)
    0 / 501 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    invasive ductal breast carcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    invasive lobular breast carcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lung neoplasm malignant
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lung adenocarcinoma stage iv
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lymphoproliferative disorder
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    metaplastic breast carcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed [3]
    0 / 488 (0.00%)
    1 / 501 (0.20%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    mucinous breast carcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    non-hodgkin's lymphoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pancreatic carcinoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    plasma cell myeloma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    prostate cancer
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed [4]
    2 / 365 (0.55%)
    1 / 373 (0.27%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    rectal cancer
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    schwannoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    aortic stenosis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    arteriosclerosis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    circulatory collapse
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    essential hypertension
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hypertensive emergency
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hypotension
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    labile hypertension
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    orthostatic hypotension
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    subclavian steal syndrome
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    asthenia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    chest pain
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    chest discomfort
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    death
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 1
         deaths causally related to treatment / all
    1 / 3
    0 / 1
    medical device site pain
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    non-cardiac chest pain
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune system disorders
    infusion related hypersensitivity reaction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    benign prostatic hyperplasia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed [5]
    2 / 365 (0.55%)
    0 / 373 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    priapism
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed [6]
    1 / 365 (0.27%)
    0 / 373 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    acute respiratory failure
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dyspnoea
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    haemoptysis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hypoxia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pneumonitis aspiration
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pneumothorax
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pulmonary embolism
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    4 / 853 (0.47%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 2
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    respiratory distress
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    respiratory arrest
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    respiratory failure
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    sleep apnoea syndrome
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    agitation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    4 / 853 (0.47%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    alcohol abuse
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    anxiety
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    behaviour disorder
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    completed suicide
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 2
    0 / 1
    confusional state
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    delirium
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    3 / 874 (0.34%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hallucination, visual
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    mental status changes
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    3 / 874 (0.34%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    mental disorder
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    suicide attempt
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    electrocardiogram qt prolonged
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    troponin increased
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    accidental overdose
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    anaesthetic complication
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    carbon monoxide poisoning
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    contusion
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    fall
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    5 / 853 (0.59%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    femur fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    femoral neck fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    forearm fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    head injury
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hip fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    infusion related reaction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lower limb fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lumbar vertebral fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    multiple fractures
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    periprosthetic fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pelvic fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pneumothorax traumatic
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    post procedural haemorrhage
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    radius fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    respiratory fume inhalation disorder
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    rib fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    road traffic accident
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    skin laceration
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    spinal compression fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    spinal fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    stress fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    sternal fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    subdural haematoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    thoracic vertebral fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    wrist fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    acute myocardial infarction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    5 / 853 (0.59%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    angina pectoris
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    atrioventricular block complete
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    atrial fibrillation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    4 / 874 (0.46%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    bradycardia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cardiac arrest
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    coronary artery disease
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    myocardial infarction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    sinus bradycardia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    sinus node dysfunction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    ventricular fibrillation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    amnesia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    amyloid related imaging abnormality-oedema/effusion
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    13 / 853 (1.52%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    13 / 13
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    4 / 853 (0.47%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    4 / 4
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    balance disorder
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cerebellar infarction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cerebrovascular accident
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cervical radiculopathy
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dementia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dementia alzheimer's type
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    dizziness
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dysarthria
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    embolic stroke
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    haemorrhagic stroke
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    ischaemic cerebral infarction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    ischaemic stroke
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    loss of consciousness
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    neurological symptom
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    presyncope
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    seizure
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    subarachnoid haemorrhage
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    syncope
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    9 / 853 (1.06%)
    13 / 874 (1.49%)
         occurrences causally related to treatment / all
    1 / 9
    0 / 13
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    transient ischaemic attack
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    3 / 874 (0.34%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    vertigo
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    visual impairment
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    abdominal discomfort
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    abdominal wall haematoma
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    colitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    diarrhoea
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    duodenitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    enterovesical fistula
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    femoral hernia strangulated
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastric ulcer perforation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastric antral vascular ectasia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastritis erosive
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastrooesophageal reflux disease
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    intestinal obstruction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    inguinal hernia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    intestinal perforation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    large intestine perforation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    large intestine polyp
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lower gastrointestinal haemorrhage
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    oesophagitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    obstruction gastric
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    obstructive pancreatitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pancreatitis acute
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pancreatitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    rectal prolapse
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    retroperitoneal haemorrhage
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    small intestinal obstruction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    small intestinal perforation
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    upper gastrointestinal haemorrhage
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    bile duct stone
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cholecystitis acute
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cholelithiasis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    erythema
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urticaria
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    acute kidney injury
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    4 / 853 (0.47%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    chronic kidney disease
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    haematuria
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    nephrolithiasis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urinary bladder haemorrhage
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urinary retention
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urinary tract obstruction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    arthralgia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    arthritis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    musculoskeletal chest pain
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    osteoporotic fracture
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    rotator cuff syndrome
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    spinal stenosis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    abscess limb
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    appendicitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    appendicitis perforated
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    bacterial sepsis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    covid-19
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    9 / 853 (1.06%)
    4 / 874 (0.46%)
         occurrences causally related to treatment / all
    0 / 9
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    covid-19 pneumonia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    3 / 874 (0.34%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    cellulitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    cystitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    diverticulitis intestinal perforated
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    diverticulitis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    enterococcal bacteraemia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    escherichia sepsis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    influenza
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    2 / 874 (0.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pelvic abscess
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pneumonia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    5 / 853 (0.59%)
    5 / 874 (0.57%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    pneumonia aspiration
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pneumonia legionella
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pyelonephritis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    sepsis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    3 / 874 (0.34%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    staphylococcal bacteraemia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    staphylococcal infection
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urinary tract infection
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    4 / 874 (0.46%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urinary tract infection pseudomonal
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    urosepsis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    decreased appetite
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dehydration
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    3 / 853 (0.35%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    diabetes mellitus inadequate control
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    diabetic ketoacidosis
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hypokalaemia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    1 / 853 (0.12%)
    0 / 874 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hyponatraemia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    2 / 853 (0.23%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hypovolaemia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    0 / 853 (0.00%)
    1 / 874 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    [6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Donanemab Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    567 / 853 (66.47%)
    425 / 874 (48.63%)
    Injury, poisoning and procedural complications
    infusion related reaction
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    73 / 853 (8.56%)
    4 / 874 (0.46%)
         occurrences all number
    166
    7
    fall
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    111 / 853 (13.01%)
    109 / 874 (12.47%)
         occurrences all number
    149
    141
    Nervous system disorders
    amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    166 / 853 (19.46%)
    65 / 874 (7.44%)
         occurrences all number
    225
    77
    amyloid related imaging abnormality-oedema/effusion
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    200 / 853 (23.45%)
    17 / 874 (1.95%)
         occurrences all number
    270
    17
    dizziness
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    52 / 853 (6.10%)
    48 / 874 (5.49%)
         occurrences all number
    59
    60
    headache
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    119 / 853 (13.95%)
    86 / 874 (9.84%)
         occurrences all number
    188
    105
    superficial siderosis of central nervous system
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    58 / 853 (6.80%)
    10 / 874 (1.14%)
         occurrences all number
    84
    12
    General disorders and administration site conditions
    fatigue
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    42 / 853 (4.92%)
    45 / 874 (5.15%)
         occurrences all number
    43
    68
    Gastrointestinal disorders
    diarrhoea
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    43 / 853 (5.04%)
    50 / 874 (5.72%)
         occurrences all number
    51
    56
    Musculoskeletal and connective tissue disorders
    arthralgia
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    49 / 853 (5.74%)
    41 / 874 (4.69%)
         occurrences all number
    55
    44
    Infections and infestations
    covid-19
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    130 / 853 (15.24%)
    150 / 874 (17.16%)
         occurrences all number
    135
    157
    urinary tract infection
    alternative dictionary used: MedDRA 25.1
         subjects affected / exposed
    42 / 853 (4.92%)
    56 / 874 (6.41%)
         occurrences all number
    52
    65

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    14 Dec 2020
    - Added titration period of 700 mg for first 3 doses; - Added instructions for when a participant does not complete the titration phase; - Added instructions for when a participant develops amyloid-related imaging abnormalities (ARIA).
    17 Feb 2021
    - Updated study to Phase 3; - Updated screening window and follow up and clarified notes in schedule of activities; - Clarification for scientific rationale for study design, justification for dose, Inclusion criteria, study interventions, efficacy and Clinical Safety laboratory assessments, Pharmacokinetics, Statistical considerations; - Modified language describing interim analyses, data monitoring committee (DMC) members description, -safety profile of flortaucipir.
    03 Sep 2021
    - Modified Number of Participants; - Added description of blinding for Cohorts 1 and 2; - Added and defined Cohorts 1 and 2; - Added details related to the Cohort 1 statistical analysis plan (SAP) and Study SAP; - Added “Interim analyses of Cohort 1 will be conducted by Lilly. Specified that other interim analyses involving Cohort 2 will be executed through the external data monitoring committee (DMC).
    05 Oct 2021
    - Clarification on schedule of Activities; - Modified description of primary endpoint. Added rationale and design details for long-term extension period; -Modified Inclusion Criteria; -Added recommendation of data monitoring committee (DMC); - Clarification on text regarding magnetic resonance imaging; - Clarification on time period and frequency for collecting AE and SAE Information; - Added clarifying text regarding Sample size determination; - Added details related to the Primary, secondary and tertiary/exploratory endpoint(s).

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 22:47:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA